<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kpccz</journal-id><journal-title-group><journal-title xml:lang="ru">Комплексные проблемы сердечно-сосудистых заболеваний</journal-title><trans-title-group xml:lang="en"><trans-title>Complex Issues of Cardiovascular Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-1278</issn><issn pub-type="epub">2587-9537</issn><publisher><publisher-name>Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17802/2306-1278-2020-9-4-114-123</article-id><article-id custom-type="elpub" pub-id-type="custom">kpccz-790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЛУЧАЙ ИЗ ПРАКТИКИ. Кардиология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE STUDY. Cardiology</subject></subj-group></article-categories><title-group><article-title>Гипертриглицеридемия - мультидисциплинарная проблема современной медицины</article-title><trans-title-group xml:lang="en"><trans-title>Hypertriglyceridemia as a multidisciplinary problem of modern medicine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0207-7063</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганкова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsygankova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цыганкова Оксана Васильевна - доктор медицинских наук, старший научный сотрудник лаборатории клинических, биохимических и гормональных исследований терапевтических заболеваний Научно-исследовательского института терапии и профилактической медицины - Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения РАН; профессор кафедры неотложной терапии с эндокринологией и профпатологией факультета повышения квалификации и профессиональной переподготовки врачей Новосибирский ГМУ.</p><p>Ул. Бориса Богаткова, 175/1, Новосибирск, 630089; Красный просп., 52, Новосибирск, 630091</p></bio><bio xml:lang="en"><p>Tsygankova Oksana V. - M.D., Ph.D., a senior researcher at the Laboratory of Clinical, Biochemical and Hormonal Studies of Therapeutic Diseases, the Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, Institute of Cytology and Genetics”, the Siberian Branch RAS; Professor at the Department of Emergency Therapy with Endocrinology and Occupational Pathology, Novosibirsk SMU.</p><p>175/1, Borisa Bogatkova, Novosibirsk, 630091; Krasny Prospect 52, Novosibirsk, 630091</p></bio><email xlink:type="simple">oksana_c.nsk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4516-6859</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ожиганова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozhiganova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ожиганова Наталья Владимировна - аспирант по направлению «внутренние болезни», младший научный сотрудник лаборатории гастроэнтерологии.</p><p>Ул. Бориса Богаткова, 175/1, Новосибирск, 630089</p></bio><bio xml:lang="en"><p>Ozhiganova Natalya V. - a postgraduate student, a research assistant at the Laboratory of Gastroenterology.</p><p>175/1, Borisa Bogatkova, Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3729-616X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашталап</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kastalap</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кашталап Василий Васильевич - доктор медицинских наук, заведующий отделом клинической кардиологии НИИ комплексных проблем сердечно-сосудистых заболеваний; доцент кафедры кардиологии и сердечно-сосудистой хирургии Кемеровский ГМУ.</p><p>Сосновый бульвар, 6, Кемерово, 650002; ул. Ворошилова, 22а, Кемерово, 650029</p></bio><bio xml:lang="en"><p>Kashtalap Vasiliy V. - M.D., Ph.D., the Head of the Department of Clinical Cardiology RI for Complex Issues of Cardiovascular Diseases; Associate Professor at the Department of Cardiology and Cardiovascular Surgery, Kemerovo SMU.</p><p>6, Sosonoviy Blvd., Kemerovo, 650002; 22a, Voroshilova St., Kemerovo, 650029</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4488-2493</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байрамова</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bayramova</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Байрамова Сабина Саяровна - младший научный сотрудник лаборатории неотложной терапии.</p><p>Ул. Бориса Богаткова, 175/1, Новосибирск, 630089</p></bio><bio xml:lang="en"><p>Bayramova Sabina S. - a research assistant at the Laboratory of Emergency Therapy.</p><p>175/1, Borisa Bogatkova, Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1913-5231</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Латынцева</surname><given-names>Л. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Latyntseva</surname><given-names>L. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Латынцева Людмила Дмитриевна - кандидат медицинских наук, заведующая терапевтическим отделением клиники, старший научный сотрудник лаборатории неотложной кардиологии.</p><p>Ул. Бориса Богаткова, 175/1, Новосибирск, 630089</p></bio><bio xml:lang="en"><p>Latyntseva Ludmila D. - Ph.D., the Head of the Therapeutic Department, a senior researcher at the Laboratory of Emergency Cardiology.</p><p>175/1, Borisa Bogatkova, Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины - филиал федерального государственного бюджетного научного учреждения Федеральный исследовательский центр Институт цитологии и генетики, Сибирское отделение Российской академии наук; Федеральное государственное бюджетное образовательное учреждение высшего образования Новосибирский государственный медицинский университет Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences; Novosibirsk State Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины - филиал федерального государственного бюджетного научного учреждения Федеральный исследовательский центр Институт цитологии и генетики, Сибирское отделение Российской академии наук<country>Россия</country></aff><aff xml:lang="en">The Institute of Internal and Preventive Medicine - a Branch of a Federal Publicly Funded Scientific Institution, the Federal Research Center “Institute of Cytology and Genetics”, the Siberian Branch of the Russian Academy of Sciences<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Федеральное государственное бюджетное научное учреждение Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Федеральное государственное бюджетное образовательное учреждение высшего образования Кемеровский государственный медицинский университет Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Research Institute for Complex Issues of Cardiovascular Diseases; Federal State Budgetary Educational Institution of Higher Education “Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2020</year></pub-date><volume>9</volume><issue>4</issue><fpage>114</fpage><lpage>123</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Цыганкова О.В., Ожиганова Н.В., Кашталап В.В., Байрамова С.С., Латынцева Л.Д., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Цыганкова О.В., Ожиганова Н.В., Кашталап В.В., Байрамова С.С., Латынцева Л.Д.</copyright-holder><copyright-holder xml:lang="en">Tsygankova O.V., Ozhiganova N.V., Kastalap V.V., Bayramova S.S., Latyntseva L.D.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nii-kpssz.com/jour/article/view/790">https://www.nii-kpssz.com/jour/article/view/790</self-uri><abstract><p>Острый панкреатит (ОП) - одна из основных причин госпитализаций по поводу заболеваний желудочно-кишечного тракта, уступающая лишь острому аппендициту. Несмотря на совершенствование методов лечения, летальность от ОП и связанных с ним осложнений до сих пор остается на высоком уровне. Гипертриглицеридемия (гиперТГ) является недооцененной причиной ОП и составляет около 10% среди других этиологических факторов. Своевременная диагностика гиперТГ, индивидуальный подход и подбор адекватной липидс-нижающей терапии позволяют снизить риски развития ОП и/или предотвратить рецидивы. В статье приводится клиническое наблюдение за пациентом с рецидивирующим течением панкреатита на фоне гиперТГ. Несмотря на высокие уровни триглицеридов и ежегодные госпитализации по поводу повторных эпизодов панкреатита, длительное время должного внимания основному этиологическому фактору не уделялось. Следовательно, не назначалась липидмо-дифицирующая терапия и не соблюдались диетические рекомендации, в том числе исключение употребления алкогольных напитков, что привело к структурным изменениям в поджелудочной железе (псевдокисте) и прогрессированию сахарного диабета за счет панкреатогенного компонента.</p></abstract><trans-abstract xml:lang="en"><p>Acute pancreatitis is one of the most common gastrointestinal causes for hospitalization after acute appendicitis. Despite recent advances in the treatment methods, mortality from acute pancreatitis and its complications remains high. Hypertriglyceridemia is an underestimated cause of acute pancreatitis, accounting for 10% among other etiological factors. Timely diagnosis of hypertriglyceridemia, a personalized approach, and the selection of adequate lipid-lowering therapy allow reducing the risk of developing and/or preventing recurrent acute pancreatitis. The article presents the clinical case of a patient with recurrent pancreatitis and hypertriglyceridemia. Despite high levels of triglycerides and annual hospitalizations for recurrent pancreatitis, the patient has not received optimal treatment for a long time. Therefore, lipid-modifying therapy has not been prescribed and none dietary recommendations have been suggested, including the exclusion of alcoholic beverages. Structural changes in the pancreas (the formation of pseudocysts) and the progression of pancreatogenic diabetes have developed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гипертриглицеридемия</kwd><kwd>панкреатит</kwd><kwd>сахарный диабет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Hypertriglyceridemia</kwd><kwd>Pancreatitis</kwd><kwd>Diabetes</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа частично выполнена по государственному заданию в рамках бюджетной темы № ААА-А-А17-117112850280-2</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Leppaniemi A., Tolonen M., Tarasconi A., Segovia-Lohse H., Gamberini E., Kirkpatrick A.W. et al. WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019; 14: 27. doi.org/10.1186/s13017-019-0247-0</mixed-citation><mixed-citation xml:lang="en">Leppaniemi A., Tolonen M., Tarasconi A., Segovia-Lohse H., Gamberini E., Kirkpatrick A.W. et al. WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019; 14: 27. doi.org/10.1186/s13017-019-0247-0</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F., Baigent C., Catapano A.L., Konstantinos K.C. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 1; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455.</mixed-citation><mixed-citation xml:lang="en">Mach F., Baigent C., Catapano A.L., Konstantinos K.C. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 1; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Y.Y., Li H.X., Zhang Y., He W.H. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019 Feb; 27(147): 101-109.</mixed-citation><mixed-citation xml:lang="en">Guo Y.Y., Li H.X., ZhangY., He W.H. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019 Feb; 27(147): 101-109.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кубышкин В.А., Затевахин И.И. Багненко С.Ф. Острый панкреатит. Клинические рекомендации. Российское общество хирургов. Ассоциация гепатопанкреатоби-лиарных хирургов стран СНГ. Москва; 2019.</mixed-citation><mixed-citation xml:lang="en">Kubyshkin V.A., Zatevahin I.I. Bagnenko S.F. Ostryj pankreatit. Klinicheskie rekomendacii.Rossijskoe obshchestvo hirurgov. Associaciya gepatopankreatobiliarnyh hirurgov stran SNG. Moskwa; 2019 (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kiss L., Fur G., Matrai P., Hegyi P., Ivany E. The effect of serum triglyceride concentration on the outcome of acute pancreatitis : systematic review and meta-analysis. Sci Rep. 2018; 8(1): 14096. doi: 10.1038/s41598-018-32337-x.</mixed-citation><mixed-citation xml:lang="en">Kiss L., Fur G., Matrai P., Hegyi P., Ivany E. The effect of serum triglyceride concentration on the outcome of acute pancreatitis : systematic review and meta-analysis. Sci Rep. 2018; 8(1): 14096. doi: 10.1038/s41598-018-32337-x.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lloret Linares C., Pelletier A.L., Czernichow S., Vergnaud A.C., Bonnefont-Rousselot D., Levy P., Ruszniewski P., Bruckert E. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13-2. doi: 10.1097/MPA.0b013e31816074a1</mixed-citation><mixed-citation xml:lang="en">Lloret Linares C., Pelletier A.L., Czernichow S., Vergnaud A.C., Bonnefont-Rousselot D., Levy P., Ruszniewski P., Bruckert E. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13-2. doi: 10.1097/MPA.0b013e31816074a1</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. doi:10.1186/s12933-015-0268-2</mixed-citation><mixed-citation xml:lang="en">Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. doi:10.1186/s12933-015-0268-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">de Pretis N., Amodio A., Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018; 6(5): 649-655. doi:10.1177/2050640618755002</mixed-citation><mixed-citation xml:lang="en">de Pretis N., Amodio A., Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018; 6(5): 649-655. doi:10.1177/2050640618755002</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T. et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Assocaition Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25; 73(24): 3168-3209. doi: 10.1016/j.jacc.2018.11.002.</mixed-citation><mixed-citation xml:lang="en">Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T. et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Assocaition Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25; 73(24): 3168-3209. doi: 10.1016/j.jacc.2018.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106: 3143-3421</mixed-citation><mixed-citation xml:lang="en">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106: 3143-3421</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Berglund L., Brunzell J.D., Goldberg A.C., Goldberg I.J., Sacks F., Murad M.H., Stalenhoef A.F. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012; 97(9): 2969-89. doi: 10.1210/jc.2011-3213.</mixed-citation><mixed-citation xml:lang="en">Berglund L., Brunzell J.D., Goldberg A.C., Goldberg I.J., Sacks F., Murad M.H., Stalenhoef A.F. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012; 97(9): 2969-89. doi: 10.1210/jc.2011-3213.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shah A.S., Wilson D.P. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015; 9(5): S20-8. doi: 10.1016/j.jacl.2015.04.004</mixed-citation><mixed-citation xml:lang="en">Shah A.S., Wilson D.P. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015; 9(5): S20-8. doi: 10.1016/j.jacl.2015.04.004</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Сергиенко И. В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: Современные аспекты патогенеза, диагностики и лечения. Москва: ООО «ПатиСС»; 2017.</mixed-citation><mixed-citation xml:lang="en">Sergienko I. V., Ansheles A.A., Kuharchuk V.V. Ateroskleroz i dislipidemii: Sovremennye aspekty patogeneza, diagnostiki i lecheniya. Moskwa: OOO «PatiSS»; 2017. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pedragosa A., Merino J., Aranda J.L., Galiana J., Godoy D., Panisello J.M., Ascaso J.F., Civeira F., Masana L., Pedro-Botet J. Clinical profile of patients with very high hypertriglyceridemia from the Registry of Hypertriglyceridemia of the SpanishAtherosclerosis Society. Clin InvestigArterioscler. 2013; 25(1): 8-15. doi: 10.1016/j.arteri.2012.11.001</mixed-citation><mixed-citation xml:lang="en">Pedragosa A., Merino J., Aranda J.L., Galiana J., Godoy D., Panisello J.M., Ascaso J.F., Civeira F., Masana L., Pedro-Botet J. Clinical profile of patients with very high hypertriglyceridemia from the Registry of Hypertriglyceridemia of the SpanishAtherosclerosis Society. Clin InvestigArterioscler. 2013; 25(1): 8-15. doi: 10.1016/j.arteri.2012.11.001</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yadav D., Pitchumoni C.S. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003 Jan; 36(1): 54-62.</mixed-citation><mixed-citation xml:lang="en">Yadav D., Pitchumoni C.S. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003 Jan; 36(1): 54-62.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Цыганкова О.В., Бадин А.Р., Старичков А.А., Ложкина Н.Г. Неалкогольная жировая болезнь печени - болезнь цивилизации или синдром современности? РМЖ. Медицинское обозрение. 2018; 3: 23-28.</mixed-citation><mixed-citation xml:lang="en">Tsygankova O.V., Badin A.R., Starichkov A.A., Lozhkina N.G. Nealkogol'naya zhirovaya bolezn' pecheni - bolezn' civilizacii ili sindrom sovremennosti? RMZH. Medicinskoe obozrenie. 2018; 3: 23-28. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш Н.А., Кувшинов Д.Ю. Питание и сердечно-сосудистое здоровье. Комплексные проблемы сердечно-сосудистых заболеваний. 2017; (2): 87-92. doi. org/10.17802/2306-1278-2017-2-87-92.</mixed-citation><mixed-citation xml:lang="en">Barbarash N.A., Kuvshinov D.Y Nutrition and Cardiovascular Health. Complex Issues of Cardiovascular Diseases. 2017;(2):87-92. (In Russian) doi.org/10.17802/2306-1278-2017-2-87-92</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Klop B., do Rego A.T., Cabezas M.C. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013 Aug; 24(4): 3216. doi: 10.1097/MOL.0b013e3283606845.</mixed-citation><mixed-citation xml:lang="en">Klop B., do Rego A.T., Cabezas M.C. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013 Aug; 24(4): 3216. doi: 10.1097/MOL.0b013e3283606845.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ewald N., Kloer H.U. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl. 2012 Jun; 7: 31-5.</mixed-citation><mixed-citation xml:lang="en">Ewald N., Kloer H.U. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl. 2012 Jun; 7: 31-5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lan J., Zhao Y., Dong F., Yan Z., Zheng W., Fan J., Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 6981.</mixed-citation><mixed-citation xml:lang="en">Lan J., Zhao Y., Dong F., Yan Z., Zheng W., Fan J., Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 6981.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobson T.A., Glickstein S.B., Rowe J.D., Soni P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012; 6: 518.</mixed-citation><mixed-citation xml:lang="en">Jacobson T.A., Glickstein S.B., Rowe J.D., Soni P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012; 6: 518.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Бенимецкая К.С., Макаренкова К.С., Цыганкова О.В., Латынцева Л.Д., Астраков С.В., Шахтшнейдер Е.В., Рагино Ю.И., Воевода М.И. Отсутствие эффекта эволоку-маба у молодой женщины с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2018; 1: 67-71.</mixed-citation><mixed-citation xml:lang="en">Benimetskaya K.S., Makarenkova K.S., Tsygankova O.V., Latyntseva L.D., Astrakov S.V., Shakhtschneider E.V., Ragino Yu.I., Voevoda M.I. The lack of the effect of evolocumab in a young woman with familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2018; 1: 67-71. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dewey F.E., Gusarova V., Dunbar R.L., O’Dushlaine C., Schurmann C., Gottesman O., et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3): 211-221. doi:10.1056/NEJMoa1612790</mixed-citation><mixed-citation xml:lang="en">Dewey F.E., Gusarova V., Dunbar R.L., O’Dushlaine C., Schurmann C., Gottesman O., et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3): 211-221. doi:10.1056/NEJMoa1612790</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gaudet D., Gipe D.A., Pordy R., Ahmad Z., Cuchel M., Shah P.K., Chyu K.Y., Sasiela W.J., Chan K.C., Brisson D., Khoury E., Banerjee P., Gusarova V., Gromada J., Stahl N., Yancopoulos G.D., Hovingh G.K. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377: 296-297. doi: 10.1056/NEJMc1705994.</mixed-citation><mixed-citation xml:lang="en">Gaudet D., Gipe D.A., Pordy R., Ahmad Z., Cuchel M., Shah P.K., Chyu K.Y., Sasiela W.J., Chan K.C., Brisson D., Khoury E., Banerjee P., Gusarova V., Gromada J., Stahl N., Yancopoulos G.D., Hovingh G.K. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377: 296-297. doi: 10.1056/NEJMc1705994.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Graham M.J., Lee R.G., Brandt T.A., Tai L.J., Fu W., Peralta R., Yu R., Hurh E., Paz E., McEvoy B.W., Baker B.F., Pham N.C., Digenio A., Hughes S.G., Geary R.S., Witztum J.L., Crooke R.M., Tsimikas S. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 2017; 377: 222-232. doi: 10.1056/NEJMoa1701329</mixed-citation><mixed-citation xml:lang="en">Graham M.J., Lee R.G., Brandt T.A., Tai L.J., Fu W., Peralta R., Yu R., Hurh E., Paz E., McEvoy B.W., Baker B.F., Pham N.C., Digenio A., Hughes S.G., Geary R.S., Witztum J.L., Crooke R.M., Tsimikas S. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 2017; 377: 222-232. doi: 10.1056/NEJMoa1701329</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Graham M.J., Lee R.G., Bell T.A. III, Fu W., Mullick A.E., Alexander V.J., Singleton W., Viney N., Geary R., Su J., Baker B.F., Burkey J., Crooke S.T., Crooke R.M. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112: 1479-1490. doi: 10.1161/CIRCRESAHA.111.300367</mixed-citation><mixed-citation xml:lang="en">Graham M.J., Lee R.G., Bell T.A. III, Fu W., Mullick A.E., Alexander V.J., Singleton W., Viney N., Geary R., Su J., Baker B.F., Burkey J., Crooke S.T., Crooke R.M. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112: 1479-1490. doi: 10.1161/CIRCRESAHA.111.300367</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Paik J., Duggan S. Volanesorsen: First Global Approval. Drugs. 2019 Aug; 79(12): 1349-1354. doi: 10.1007/s40265-019-01168-z.</mixed-citation><mixed-citation xml:lang="en">Paik J., Duggan S. Volanesorsen: First Global Approval. Drugs. 2019 Aug; 79(12): 1349-1354. doi: 10.1007/s40265-019-01168-z.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jiao Y., Lu Y., Li X.Y. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015; 36(1): 44-50. doi:10.1038/aps.2014.116</mixed-citation><mixed-citation xml:lang="en">Jiao Y., Lu Y., Li X.Y. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015; 36(1): 44-50. doi:10.1038/aps.2014.116</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
